Spironolactone
- Generic Name
- Spironolactone
- Brand Names
- Aldactazide, Aldactone, Carospir, Qaialdo
- Drug Type
- Small Molecule
- Chemical Formula
- C24H32O4S
- CAS Number
- 52-01-7
- Unique Ingredient Identifier
- 27O7W4T232
- Background
Spironolactone is a potassium-sparing diuretic. It binds to mineralocorticoid receptors and functions as aldosterone antagonists. It promotes sodium and water excretion and potassium retention. Spironolactone was originally developed purely for this ability before other pharmacodynamic properties of the drug were discovered. It is indicated to treat several ...
- Indication
Spironolactone is indicated for the treatment of the following conditions:
As spironolactone has antiandrogenic activity, its off-label uses include the treatment of hirsutism, female pattern hair loss, and adult acne vulgaris.
- Associated Conditions
- Edema, Hypertension, Primary Aldosteronism, Primary Hyperaldosteronism, Secondary hyperaldosteronism, Chronic heart failure with reduced ejection fraction (NYHA Class III), Chronic heart failure with reduced ejection fraction (NYHA Class IV), Idiopathic hyperaldosteronism, Refractory Edema
- Associated Therapies
- Perioperative drug treatment, Maintenance therapy
Effects of Spironolactone on Collagen Metabolism in Patients With Pulmonary Arterial Hypertension
- First Posted Date
- 2011-11-09
- Last Posted Date
- 2015-05-08
- Lead Sponsor
- Baylor College of Medicine
- Target Recruit Count
- 50
- Registration Number
- NCT01468571
- Locations
- 🇺🇸
Baylor College of Medicine, Houston, Texas, United States
Effect of Spironolactone on Adrenal or Ovarian Androgen Production in Overweight Pubertal Girls With Androgen Excess
- Conditions
- Interventions
- First Posted Date
- 2011-08-24
- Last Posted Date
- 2023-10-27
- Lead Sponsor
- University of Virginia
- Target Recruit Count
- 20
- Registration Number
- NCT01422759
- Locations
- 🇺🇸
University of Virginia Center for Research in Reproduction, Charlottesville, Virginia, United States
Mineralocorticoid Receptor and Obesity Induced Cardiovascular Complications
- Conditions
- Interventions
- First Posted Date
- 2011-07-29
- Last Posted Date
- 2017-04-28
- Lead Sponsor
- Brigham and Women's Hospital
- Target Recruit Count
- 38
- Registration Number
- NCT01406015
- Locations
- 🇺🇸
Brigham and Women's Hospital, Boston, Massachusetts, United States
The Effect of Amiloride and Spironolactone in Patients With Hypertension
- First Posted Date
- 2011-07-06
- Last Posted Date
- 2012-03-28
- Lead Sponsor
- Erling Bjerregaard Pedersen
- Target Recruit Count
- 23
- Registration Number
- NCT01388088
- Locations
- 🇩🇰
Department of Medical Research, Holstebro, Denmark
Patiromer in the Treatment of Hyperkalemia in Patients With Hypertension and Diabetic Nephropathy (AMETHYST-DN)
- Conditions
- Interventions
- First Posted Date
- 2011-06-13
- Last Posted Date
- 2021-06-03
- Lead Sponsor
- Relypsa, Inc.
- Target Recruit Count
- 324
- Registration Number
- NCT01371747
- Locations
- 🇬🇪
Investigator Site 311, Tbilisi, Georgia
🇬🇪Investigator Site 303, Tbilisi, Georgia
🇬🇪Investigator Site 308, Tbilisi, Georgia
BAY94-8862 Dose Finding Trial in Subjects With Chronic Heart Failure and Mild (Part A) or Moderate (Part B) Chronic Kidney Disease
- Conditions
- Interventions
- First Posted Date
- 2011-05-02
- Last Posted Date
- 2022-02-10
- Lead Sponsor
- Bayer
- Target Recruit Count
- 457
- Registration Number
- NCT01345656
A Single Dose Study Of Antimineralocorticoid Activity Of PF-03882845 In Healthy Volunteers
- Conditions
- Interventions
- First Posted Date
- 2011-03-15
- Last Posted Date
- 2011-07-06
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 12
- Registration Number
- NCT01314898
- Locations
- 🇺🇸
Pfizer Investigational Site, New Haven, Connecticut, United States
Evaluation of Cortisol Resistance in Young Sedentary and Endurance-Trained Men
- Conditions
- Interventions
- First Posted Date
- 2011-02-11
- Last Posted Date
- 2024-07-15
- Target Recruit Count
- 51
- Registration Number
- NCT01294319
- Locations
- 🇺🇸
National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States
The Effects of Amiloride and Spironolactone on Renophysiological and Cardiovascular Variables
- Conditions
- Interventions
- First Posted Date
- 2010-09-06
- Last Posted Date
- 2015-08-20
- Lead Sponsor
- Regional Hospital Holstebro
- Target Recruit Count
- 25
- Registration Number
- NCT01195805
- Locations
- 🇩🇰
Departments of medical research and medicine, Holstebro, Denmark
Evaluation of Patiromer Titration in Heart Failure Patients With Chronic Kidney Disease
- First Posted Date
- 2010-05-26
- Last Posted Date
- 2021-05-12
- Lead Sponsor
- Relypsa, Inc.
- Target Recruit Count
- 63
- Registration Number
- NCT01130597
- Locations
- 🇬🇪
Investigator Site 11, Tbilisi, Georgia
🇬🇪Investigator Site 12, Tbilisi, Georgia
🇸🇮Investigator Site 22, Maribor, Slovenia
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.